ClinicalTrials.gg
Not yet recruitingNCT07714135Updated Jul 21, 2026

Evaluation of an Oat Fiber Supplement on Health

An interventional study of Oat Fiber and Placebo in Supplementation Efficacy in Health Adults on Plasticizer Removal, sponsored by California Polytechnic State University-San Luis Obispo. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by California Polytechnic State University-San Luis Obispo · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of the study is to determine whether short-term use of an oat fiber supplement reduces exposure to your urine levels of dietary chemicals like bisphenol A (BPA).

This study will also examine whether supplementation with NeutraOat oat fiber influences blood glucose levels using continuous glucose monitoring.

Read the detailed description

The purpose of this study is to evaluate whether short-term supplementation of oat fiber reduces exposure to plasticizers following a controlled dietary exposure and whether any resulting changes influence glycemic responses.

02

Conditions studied

  • Supplementation Efficacy in Health Adults on Plasticizer Removal

Keywords

  • Oat FIber
  • supplementation
  • metabolic health
  • BPA
03

In context

Lead sponsor

California Polytechnic State University-San Luis Obispo is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants will be healthy
  • Weight-stable for the previous 6 months
  • Free of any metabolic or chronic disease
  • Non-smoking (to include vaping and other nicotine or THC containing products)
  • Participate in less than 250 minutes of moderate to vigorous physical activity per week

Exclusion criteria

Exclusion Criteria:

  • Any chronic or metabolic disease, including type 1 or type 2 diabetes
  • Gastrointestinal (GI) diseases/disorders
  • Neurologic or psychiatric conditions
  • Nicotine or THC consumption
  • Unsafe dieting practices
  • Special diets (e.g. vegan, low-carbohydrate, gluten-free, dairy-free, etc.)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Oat Fiber Supplement

    4 grams of supplementation by capsule per day for two days

    Dietary Supplement: Oat Fiber

  • Placebo comparator
    Placebo

    4 grams of supplementation (placebo) by capsule per day for two days

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementOat Fiber

    4 grams of supplementation by capsule per day for two days

  • Dietary supplementPlacebo

    4 grams of supplementation (placebo) by capsule per day for two days

06

What researchers measure

Primary outcomes

  1. Urine Plasticizer Concentration

    Plasticizer concentration in urine samples measured before and after oat fiber supplementation.

    Time frame: Urine samples will be take over the course of three weeks.

Secondary outcomes

  1. Blood Glucose Levels

    Blood glucose levels before and after supplementation with oat fiber.

    Time frame: Blood glucose levels will be monitored over the course of 3 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be available on the Cal Poly Digital Commons website and available upon request.

Supporting information: Study protocol, Informed consent form

Time frame: July 2026 until September 2027

Access criteria: Available to download

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714135
Lead sponsor
California Polytechnic State University-San Luis Obispo
Responsible party
Todd Hagobian (Kinesiology and Public Health Professor and Department Chair, California Polytechnic State University-San Luis Obispo) — Principal investigator
First posted
Jul 20, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Todd Hagobian, PhD
Contact
thagobia@calpoly.edu
805-756-7511

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion